Nuclea, Thermo Fisher Collaborating on Mass Spec Assays for Type 2 Diabetes | GenomeWeb

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and Thermo Fisher Scientific said today that they are collaborating on multiplexed mass spec assays for quantifying native insulin and its therapeutic analogs.

Nuclea plans to use the assays to analyze patient samples as part of the company's diabetes research collaborations.

The assays will be developed at Thermo Fisher's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and will be run using Thermo Fisher's MSIA immunoenrichment technology and its TSQ Vantage or Quantiva mass spec instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.